Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ainos, Inc. - warrants (NQ:AIMDW)

0.0751 -0.0409 (-35.26%)
Streaming Delayed Price Updated: 9:59 AM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ainos, Inc. - warrants

< Previous 1 2 3 4 5 Next >
News headline image
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Via ACCESSWIRE
News headline image
Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Ainos Announces $1.75 Million Follow-On Funding
Via ACCESSWIRE
News headline image
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
Via ACCESSWIRE
News headline image
Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical
Via ACCESSWIRE
News headline image
Ainos Reports Third Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement
Via ACCESSWIRE
News headline image
Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan
Via ACCESSWIRE
News headline image
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell
Via ACCESSWIRE
News headline image
Ainos, Inc. Announces Stock Consolidation
Via ACCESSWIRE
News headline image
Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA
Via ACCESSWIRE
News headline image
Ainos’ VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients
Via ACCESSWIRE
News headline image
Ainos Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Ainos Celebrates First Listing Anniversary on Nasdaq
Via ACCESSWIRE
News headline image
Ainos Issues Mid-Year Business Update Letter to Shareholders
Via ACCESSWIRE
News headline image
Ainos Provides Insights Into Its AI Nose Technology
Via ACCESSWIRE
News headline image
Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target
Via ACCESSWIRE
News headline image
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption
Via ACCESSWIRE
News headline image
Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target
Via ACCESSWIRE
News headline image
Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales
Via ACCESSWIRE
News headline image
Ainos Appoints Amanda Sung as New Chief Financial Officer
Via ACCESSWIRE
News headline image
Ainos Reports First Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
Ainos Reports Fourth Quarter and Full Year 2022 Financial Results
Via ACCESSWIRE
News headline image
Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan
Via ACCESSWIRE
News headline image
Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug
Via ACCESSWIRE
News headline image
Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients
Via ACCESSWIRE
News headline image
Ainos Announces US$3 Million Convertible Notes Private Placement
Via ACCESSWIRE
News headline image
Ainos Issues 2023 Shareholder Letter
Via ACCESSWIRE
News headline image
Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization
Via ACCESSWIRE
News headline image
Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.